Exo-Top

Exo-Top

NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology

Calgary, Alberta and Oxford, United Kingdom–(Newsfile Corp. – October 12, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company’s wholly-owned subsidiary, NurExone Biologic Ltd., signed

Read More »
October 23, 2022

Interview mit Dr. Lior Shaltiel, CEO & Director von NurExone Biologic Inc.

Woher kommt diese Exosome-Technologie? – Wieso gerade jetzt der Börsengang? – Exosome können wir also auch mit Informationen bestücken, wie sie etwas heilen oder reparieren müssen? – Kann man diese Technologie auch gegen Krebs und Tumore verwenden? – Kommen wir zur Querschnittslähmung, hier sind ja die Nervenstränge getrennt. Wie bringe

Read More »
October 19, 2022

NurExone Announces Scientific Survey Results of Proprietary Exosome-based Technology

Calgary, Alberta–(Newsfile Corp. – October 4, 2022) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced today results from a controlled survey in the Company’s lab showing the effectiveness of the

Read More »
October 19, 2022

Set layout popup